Jill Gilbert
Overview
Explore the profile of Jill Gilbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
3417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Rivero J, Else T, Hallanger-Johnson J, Kiseljak-Vassiliades K, Raj N, Reidy-Lagunes D, et al.
Oncologist
. 2024 Jul;
29(9):747-760.
PMID: 39037424
Importance: Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and European Medicines Agency-approved product for the treatment of adrenocortical carcinoma. Observations: Mitotane is challenging...
2.
Cooper W, Hickson G, Dmochowski R, Domenico H, Barr F, Emory C, et al.
JAMA Netw Open
. 2024 Jun;
7(6):e2415331.
PMID: 38842804
Importance: Because unprofessional behaviors are associated with patient complications, malpractice claims, and well-being concerns, monitoring concerns requiring investigation and individuals identified in multiple reports may provide important opportunities for health...
3.
Le X, Baik C, Bauman J, Gilbert J, Brose M, Grilley-Olson J, et al.
Oncologist
. 2022 May;
PMID: 35536733
Background: Larotrectinib is a first-in-class, highly selective, and central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer. We...
4.
Cardin D, Gilbert J, Whisenant J, Ayers G, Jalikis F, Dahlman K, et al.
Clin Colorectal Cancer
. 2022 Apr;
21(3):236-243.
PMID: 35450836
Introduction: Small bowel adenocarcinomas (SBAs) are rare and frequently treated like large intestinal adenocarcinomas. However, SBAs have a very different microenvironment and could respond differently to the same therapies. Our...
5.
Sheth S, Gilbert J, Deal A, Chera B, Murphy B, Woods J, et al.
Oral Oncol
. 2022 Mar;
127:105807.
PMID: 35263677
No abstract available.
6.
Martin 3rd R, Grant M, Kimani S, Midha S, May J, Patell R, et al.
JCO Oncol Pract
. 2021 Jul;
18(1):e36-e46.
PMID: 34242082
Purpose: COVID-19 challenged medical practice and graduate medical education. Building on previous initiatives, we describe and reflect on the formative process and goals of the Hematology-Oncology Collaborative Videoconferencing Learning Initiative,...
7.
Deng J, Dietrich M, Niermann K, Sinard R, Cmelak A, Ridner S, et al.
Int J Radiat Oncol Biol Phys
. 2020 Oct;
109(3):747-755.
PMID: 33068688
Purpose: Lymphedema and fibrosis (LEF) are common yet overlooked late effects of head and neck cancer and its therapy. Lack of reliable and valid measures of head and neck LEF...
8.
Smith D, Cmelak A, Niermann K, Ghiam M, Lou D, Gilbert J, et al.
Head Neck
. 2020 Aug;
42(12):3497-3505.
PMID: 32770612
Background: Radiation for patients with head and neck cancer (HNC) is associated with painful mucositis that impacts the delivery of treatment and contributes to high symptom burden. Methods: This was...
9.
Chiang A, Sequist L, Gilbert J, Conkling P, Thompson D, Marcoux J, et al.
Clin Lung Cancer
. 2020 Jun;
21(5):455-463.e4.
PMID: 32586767
Background: Programmed death-ligand 1 (PD-L1) protein is expressed in various cancers, including small-cell lung cancer (SCLC). Atezolizumab inhibits PD-L1 signaling, thus restoring tumor-specific T-cell immunity. Here, we report results from...
10.
Argiris A, Li S, Savvides P, Ohr J, Gilbert J, Levine M, et al.
J Clin Oncol
. 2019 Oct;
37(34):3266-3274.
PMID: 31618129
Purpose: We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma of the head...